Trustees’ Annual Report for the period
| Period start date | Period start date | Period start date | Period end date | Period end date | |||
|---|---|---|---|---|---|---|---|
| Day | Month | Year | Day | Month | Year | ||
| From | 23 | June | 2024 | To | 22 | June | 2025 |
| Charity name | Radiotherapy UK | ||||||
| Other names charity is known by | ACCORN | ||||||
| Action Radiotherapy | |||||||
| Charity registration number | 1135902 |
Objectives and Activities
| SORP reference | ||
|---|---|---|
| Summary of the purposes of the charity as set out in its governing document |
Para 1.17 | 1. To promote, support and encourage research into radiotherapy, radiobiology and allied subjects, and the dissemination of the useful results of such research by such actions as: a. Promoting and facilitating multidisciplinary collaboration between researchers and practitioners in radiotherapy and its allied subjects b. Informing patients and the public about practice and research in radiotherapy and its allied subjects, and engaging patients and the public in the development of research projects c. Awarding grants as appropriate 2. To advance and benefit the practice of radiotherapy and its allied subjects to relieve sickness and preserve good health by such actions as: a. Promoting and facilitating multidisciplinary networking and sharing of expertise and best practice b. Promoting and encouraging the study of the science and practice of radiotherapy and its allied subjects c. Promoting and facilitating increased involvement of allied professions d. Facilitating development and dissemination of best practices in radiotherapy and its allied subjects e. Disseminating knowledge concerning all aspects of the science and practice of radiotherapy and its allied subjects f. Promoting and facilitating education and training in the research and practice of radiotherapy and its allied subjects |
| Summary of the main actvites in relaton to those purposes for the public beneft, in partcular, the actvites, projects or services identfed in the accounts. |
Para 1.17 and 1.19 |
1. Patent informaton resources We work to support patents with cancer through the provision of trusted, accessible and relevant informaton resources before, during and following their radiotherapy treatment. We develop Patent Informaton Forum (PIF) accredited resources that means patents and families can trust that what we produce is evidence-based, understandable, jargon-free, up-to-date and produced to the best possible standard. 2. Advocacy and Campaigning We work in partnership with patents, academics, workforce, industry and parliamentarians to campaign for equality of access to world-class radiotherapy for all patents with cancer in the UK. We raise awareness of how harnessing technologically advanced, cost-efectve radiotherapy could treat more patents, quicker. We are proud to be the charity partner of the Radiotherapy4Life campaign and co-founder of the #CatchUpWithCancer campaign. As Secretariat for the APPG- Radiotherapy we work with the Chair and Ofcers in organising events, meetngs and ensuring all APPG regulatons and requirements are met. Our work also has global reach through our partnership with the Global Coaliton for Radiotherapy as we support other countries advocatng for increased access to radiotherapy services. 3. Workforce engagement and support Our work amplifes the voice of the frontline radiotherapy workforce to raise awareness of the issues faced in the delivery of services. We provide opportunites for the workforce to learn and engage with ideas, innovatons and technologies that can support them in developing patent- centred care and practce. We ofer an actve network of radiotherapy professionals who ofer peer support, educaton and insight. We also promote careers in radiotherapy through job listngs shared daily through our platorms and website. 4.General fundraising/events The charity raises funds from a variety of sources including online giving, community events, corporate partnerships, legacies, individual donatons and grants. The charity was very grateful to receive support in this fnancial year from B-Clear, Ergea, Brainlab, Elekta, Varian-Siemens-Healthineers, FlenHealth, Amethyst, AstraZeneca, Price-Jones, Accuray and the Openworks Foundaton. 5. Research and Data The charity delivers analysis on publicly available data such as waitng-tmes for cancer treatment and produces evidence- based reports and research to beter understand how radiotherapy services are currently being delivered and what needs to change to improvepatent outcomes and |
|---|---|---|
| experience. We collaborate and support research partners to co-design and deliver patent-focused research projects. |
||
|---|---|---|
| 4 | Para 1.18 | Radiotherapy UK has had regard to the guidance issued by the Charity Commission on public beneft. Radiotherapy UK is commited to making available to the public, informaton regarding radiotherapy treatment and its benefts, providing opportunites for radiotherapy professionals to share informaton as well as campaign for beter fundingfor radiotherapytreatment in the UK. |
Additional information (optional)
You may choose to include further statements where relevant about:
| Contributon made by volunteers | Para 1.38 | Volunteers are essental to our charity's success in delivering services. We depend on them to lead our organizaton through the Board, and to guide our eforts via the Ambassadors network, as well as patent and clinical engagementgroups. |
|---|---|---|
Achievements and Performance
| Achievements and Performance | |||
|---|---|---|---|
| SORP reference | |||
| Summary of the main achievements of the charity, identfying the diference the charity’s work has made to the circumstances of its benefciaries and any wider benefts to society as a whole. |
Para 1.20 | In additon to the actvites noted above ,the charity has achieved the following this year for the beneft of patents, professionals, and the wider community: Advocacy and Policy We co-ordinated three high-profle events at Westminster, engaging over 75 MPs through our #CatchUpWithCancer_and_Radiotherapy4Life campaigns. A major milestone was our_#CatchUpWithCancer_ Day in Parliament on World Cancer Day 2025, bringing together over 20 cancer charites and earning natonal media coverage for our analysis revealing that more than 500,000 people have faced excessive delays in cancer treatment over the past decade. In Autumn 2025, thegovernment announced £70 million for replacing radiotherapy machines, refectng with one of our campaign’s key calls to acton. We amplifed our advocacy work at four major conferences, presentng natonally and internatonally—including UKIO, the SCOR Annual Conference, and an Internatonal Cancer Expert Corps event at CERN, Switzerland. The charity supported the development of the world’s frstWorld Radiotherapy Awareness Day |
| (WRAD). Developed in partnership with founding | |
|---|---|
| organisaton Global Coaliton for Radiotherapy, the | |
| day highlighted the need for natonal and | |
| internatonal advocacy to improve access to | |
| radiotherapy for all patents globally. | |
| | Parliamentary engagement included 130 Writen |
| Questons and one dedicated debate on Accessibility | |
| to Radiotherapy on World Cancer Day 2025. | |
| | Our_CatchUpWithCancer_petton surpassed 624,919 |
| signatures onchange.org petton . |
|
| | We launched our landmark report,Unlocking |
| Modern Radiotherapy ,providing critcal analysis and |
|
| recommendatons to transform patent access. | |
| | Radiotherapy UK contnued as secretariat for theAll- |
| Party Parliamentary Group for Radiotherapy (APPG- |
|
| RT). Following the electon of a new government, the | |
| APPG was successfully reconsttuted, ending the | |
| period with 41 MP members. | |
| Patent | Informaton |
| | Launched ourPatents and Families Online Hub – a |
| major milestone packed with resources to support | |
| patents and their loved ones throughout the | |
| radiotherapy pathway. | |
| | Successfully renewed our PIF TICK accreditaton |
| following rigorous independent assessment – | |
| maintaining our status as a_trusted informaton_ | |
| _creator_and holding the UK’s only assessed quality | |
| mark for health and care informaton. | |
| | Created over 45 new patent informaton resources, |
| ensuring clarity and accessibility for those navigatng | |
| treatment. | |
| | Hosted 8 meetngs of our Patent Engagement |
| Group, strengthening patent voice in our work. | |
| | Engaged 10 patent reviewers and 20 clinical |
| reviewers to support the development of high- | |
| quality patent informaton resources. | |
| | Our new Patents and Families Online Hub have |
| driven signifcant increase in visits to our website | |
| with 56,000 new users over this period, representng | |
| a 40% increase in new users from previous period_._ | |
| | We are project partners of the GRACE project, |
| (Gynae Radiotherapy Consent Enhancement), | |
| research led by Lancaster and Bangor universites | |
| and funded by NIHR. GRACE aims to improve how | |
| patents make informed decisions about | |
| radiotherapy for gynaecological cancer, with input | |
| from clinical experts, researchers, those with lived | |
| experience and thepublic. |
Workforce Engagement
| | Delivered four RTUK Talks webinars, atractng 1,221 |
|---|---|
| registratons and generatng 479 YouTube views, | |
| providing valuable learning and networking | |
| opportunites for the radiotherapy workforce. | |
| | Expanded our Workforce Ambassadors programme, |
| now engaging 50 ambassadors who champion best | |
| practce and workforce development across the UK. | |
| | Launched the 2024 Flash Workforce Survey, with |
| responses from just under 10% of the workforce, | |
| helping to inform and strengthen our advocacy work | |
| by amplifying the voice of frontline professionals. | |
| Communicatons and Awareness |
| | Maintained a strong media presence, with regular |
|---|---|
| coverage in natonal news and major print | |
| publicatons.(All coverage is availablehere .) |
|
| | Signifcant growth across key digital channels, in line |
| with our communicatons strategy: | |
oDaily News: 1,964 subscribers |
|
oInstagram: 22% increase in followers (from |
|
| 2,538 to 3,100) | |
oLinkedIn: 24.3% growth (from 6,554 to |
|
| 8,153 followers) | |
oFacebook: 6.5% growth (from 2,538 to |
|
| 3,100 followers) | |
| | Website trafc surged, with a 40% increase in new |
| users, reaching 56,000. | |
| | YouTube engagement grew, with 9,406 views and |
| 485.9 watch hours, expanding our reach through | |
| video content. | |
| ern | ance |
| | Recruited six new Board members, bringing fresh |
| expertse and perspectves to strengthen leadership | |
| and oversight. | |
| | Developed the 2025–2028 Strategic Plan, setng a |
| clear roadmap for growth, impact, and sustainability. |
Governance
| Additional information (optional) You may choose to include further statements where relevant about: |
Additional information (optional) You may choose to include further statements where relevant about: |
Additional information (optional) You may choose to include further statements where relevant about: |
|---|---|---|
| Achievements against objectves set |
Para 1.41 | N/A |
| Performance of fundraising actvites against objectves set |
Para 1.41 | N/A |
| Other | Corporate Partnerships The charity benefts from several corporate partnerships for example Varian (Siemens Healthineers) and Ergea co-sponsor the charity’s Daily News bulletn. All these partnerships are agreed on a vendor neutral basis. |
|
| Financial Review | ||
| Review of the charity’s fnancial positon at the end of the period |
Para 1.21 | The Charity’s total income for this fnancial year was £214,611. Total expenditure for this year was £201,658 leaving the charity with a year-end net proft of £12,953 During 2024/2025 The Charity has managed to contnue its work within budget by using its contacts and generous donatons in kind (resources) from Price Jones Ltd. With the current economic constraints and cost of living crisis this is a challenging tme for charity income generaton. However, the charity is confdent that there are untapped avenues of funding available to the organisaton. In this year the charity hired a part-tme fundraiser to support with accessing this funding. |
| Statement explaining the policy for holding reserves statng why they are held |
Para 1.22 | Radiotherapy UK’s policy is to provide the charity with adequate fnancial stability and the means for it to meet its charitable objectves. Except for such funds as the Trustees consider prudent to maintain for the purposes of management and administraton of the charity for the foreseeable future, all unrestricted funds are used to the purpose of general objects of the charity. The adequacy of the reserves is reviewed annually. |
| Amount of reserves held | Para 1.22 | £163,577 (excluding the related party loan mentoned below) |
| Details of fund materially in defcit | Para 1.24 | The Charity has a long-term interest-free loan from related party Price Jones Ltd which is repayable at £2,500pa. The balance at June 2025 is £12,672. |
| Explanaton of any uncertaintes about the charity contnuing as a goingconcern |
Para 1.23 | There are no current uncertaintes regarding the charity contnuing as a going concern. |
| Additional information (optional) You may choose to include further statements where relevant about: |
||
| The charity’s principal sources of funds(includinganyfundraising) |
Para 1.47 | The Charity’s main source of funds for this reportng period were: |
| 1. Public Donatons via online giving and community events. 2. Corporate donatons 3. Legacies |
||
|---|---|---|
| Investment policy and objectves including any social investment policyadopted |
Para 1.46 | We do not currently hold enough reserves to warrant an investment policy. |
| A descripton of the principal risks facing the charity |
Para 1.46 | Current Challenges 1. Balancing growth with fnancial constraints– expanding services while managing limited resources. 2. Strained fundraising environment– cost-of-living crisis and economic uncertainty making donor engagement and income generaton more difcult. 3. Maintaining benefciary engagement– ensuring patents and service users remain actvely involved in services and organisatonal development. 4. Strengthening governance structures– adaptng policies and oversight to match organisatonal growth and complexity. 5. Navigatng a shifing politcal and health landscape– responding to policy changes and advocacy needs in an unpredictable environment both natonally and geopolitcally. 6. Healthcare system pressures– ongoing crisis in cancer service delivery, compounded by workforce strikes, excessive bureaucracy, leadership gaps, and minimal investment. 7. Keeping pace with technology and AI– leveraging digital tools and artfcial intelligence for service delivery, fundraising, and communicatons while managing costs, skills gaps, and ethical consideratons. |
| Other | Future initatves 1. Implement Year One of the 2025–2028 Strategic Plan, setng the foundaton for long-term impact. 2. Develop new income generaton streamsto strengthen fnancial sustainability and support service growth. 3. Engage with the new Cancer Control Plan, ensuring our approach is evidence-based and data-driven. 4. Deliver new patent informaton resources, including comprehensive skin-care guidelines and a major project on internal radiotherapy. 5. Expand collaboraton with like-minded organisatons, natonally and internatonally, to amplify reach and infuence. 6. Contnue campaigning and advocacy efortsto secure improved access to high-quality radiotherapy services across the UK. 7. Strengthen workforce engagementthrough the contnued growth of our Workforce Ambassadors Programme, supportng professional development and advocacy. 8. Advance the APPG-RT programme of work, with a focus on tackling inequalites in access to radiotherapy services. 9. Collaborate with research partners across all areas, including projects aimed at improving patent experience and supportng the adopton of new radiotherapy techniques. |
|||
|---|---|---|---|---|
Structure, Governance and Management
| Descripton of charity’s trusts: | ||
|---|---|---|
| Type of governing document (trust deed, royal charter) |
Para 1.25 | Consttuton |
| How is the charity consttuted? (e.g. unincorporated associaton, CIO) |
Para 1.25 | Associaton |
| Trustee selecton methods including details of any consttutonal provisions e.g. electon to post or name of any person or body enttled to appoint one or more trustees |
Para 1.25 | Original Trustees were nominated and elected by the ACORRN Scientfc Steering Commitee. New Trustees are nominated by the same process and are elected by consensus of the Board of Trustees of Radiotherapy UK. |
Reference and Administrative details
| Charityname | RadiotherapyUK(previouslyActon Radiotherapy) |
|---|---|
| Other name the charityuses | ACORRN |
| Registered charitynumber | 1135902 |
| Charity’s principal address | 4 Abbotsbury House 139 Abbotsbury Road London W14 8EN |
Names of the charity trustees who manage the charity
| 1 2 3 4 5 6 7 8 9 10 11 |
Trustee name | Ofce (if any) | Dates acted if not for whole year |
Name of person (or body) enttled to appoint trustee (if any) |
|---|---|---|---|---|
| Professor Patricia Price | Chair | Board of Trustees | ||
| Dr Christy Goldsmith | Secretary | Board of Trustees | ||
| Ms Tanya Levine | Treasurer | Board of Trustees | ||
| Dr Clive Harmer | Resigned 1.2.25 | Board of Trustees | ||
| Professor Philip Mayles | Board of Trustees | |||
| Victoria Chapman | Appointed 12.9.24 | Board of Trustees | ||
| Samina Hussain | Appointed 12.9.24 | Board of Trustees | ||
| Professor Andrew Beavis | Appointed 12.9.24 | Board of Trustees | ||
| Adele Lyons | Appointed 12.9.24 | Board of Trustees | ||
| Andy Tudor | Appointed 12.9.24 | Board of Trustees | ||
| Dr Clare Louise Hague | Appointed 12.9.24 | Board of Trustees |
Funds held as custodian trustees on behalf of others
| Descripton of the assets held in this capacity |
None |
|---|---|
| Name and objects of the charity on whose behalf the assets are held and how this falls within the custodian charity’s objects |
None |
| Details of arrangements for safe custody and segregaton of such assets from the charity’s own assets |
None |
Additional information (optional)
Names and addresses of advisers (Optional information)
==> picture [208 x 10] intentionally omitted <==
----- Start of picture text -----
Type of adviser Name Address
----- End of picture text -----
Name of chief executive or names of senior staff members (Optional information) Sarah Quinlan – Charity Director
Exemptions from disclosure
Reason for non-disclosure of key personnel details
Other optional information
Declarations
| The trustees declare that they have approved the trustees’ report above. Signed on behalf of the charity’s trustees ~~oo~~ |
The trustees declare that they have approved the trustees’ report above. Signed on behalf of the charity’s trustees ~~oo~~ |
The trustees declare that they have approved the trustees’ report above. Signed on behalf of the charity’s trustees ~~oo~~ |
|---|---|---|
| Signature(s) | ||
| Full name(s) | Professor Pat Price | |
| Position (e.g. Secretary, Chair, etc | Chair | |
| Date | 16 December 2025 |
Radiotherapy UK
Receipts and pay 23.06.2024 For the period from ~~ee~~
~~a~~ Section A Receipts and payments Unrestricted Restricted funds funds
to the nearest £
to the nearest £
A1 Receipts
| A1 Receiptsptsts | |||
|---|---|---|---|
| Corporate donations | 156,167 | - | |
| Community | 22,814 | - | |
| Trusts & Foundations | 5,599 | - | |
| Legacies | 30,000 | - | |
| Interest Income | 31 | - | |
| - | - | ||
| - | - |
214,611 - Sub total (Gross income for AR)
| 214,611 - Sub total(Gross income for AR) |
214,611 - Sub total(Gross income for AR) |
214,611 - Sub total(Gross income for AR) |
214,611 - Sub total(Gross income for AR) |
214,611 - Sub total(Gross income for AR) |
214,611 - Sub total(Gross income for AR) |
214,611 - Sub total(Gross income for AR) |
214,611 - Sub total(Gross income for AR) |
214,611 - Sub total(Gross income for AR) |
|---|---|---|---|---|---|---|---|---|
| - - - - Sub total - - A2 Asset and investment sales, (see table). ~~————~~ |
||||||||
| Total receipts 214 A3 Payments |
214,611 ~~ee ~~ |
|||||||
| Advocacy& campaigning | 22,018 | - | ||||||
| Charityrunningcosts | 4,690 | - | ||||||
| Communications | 5,550 | - | ||||||
| Contractors | 76,071 | - | ||||||
| Incomegeneration | 89 | - | ||||||
| IT & development | 2,250 | - | ||||||
| Patient services | 920 | - | ||||||
| Professional fees | 5,105 | - | ||||||
| Promotional materials | 2,979 | - | ||||||
| Research & Data analytics | - | - | ||||||
| Salaries | 73,431 | - | ||||||
| Workforce services | 2,248 | - | ||||||
| Training& development | 3,807 | - | ||||||
| Loan repayment | 2,500 | - |
Sub total ~~ee~~ 201,658 ~~|~~ -
A4 Asset and investment purchases, (see table) Computer equipment - ~~—————~~
| Sub total - Total payments 201,658 Net of receipts/(payments) 12,953 A5 Transfers between funds - A6 Cash funds last year end 150,624 Cash funds this year end 163,577 |
- |
|---|---|
| - | |
| - | |
| - | |
| - | |
| - |
Section B Statement of assets and liabilities at the end
Categories
Details
B1 Cash funds
Bank
Total cash funds
(agree balances with receipts and payments account(s))
Details
B2 Other monetary assets
Details
B3 Investment assets
Details
B4 Assets retained for the charity’s own use
Details
B5 Liabilities
Signed by one or two trustees on behalf of all the trustees
Loan due to Professor Pat Price Limited
Signature
1135902 ments accounts 22.06.2025 To
CC16a
Endowment funds Total funds
Last year
to the nearest £ to the nearest £ to the nearest £
| - | 156,167 | 91,431 | ||
|---|---|---|---|---|
| - | 22,814 | 23,208 | ||
| - | 5,599 | 2,470 | ||
| - | 30,000 | |||
| - | 31 | - | ||
| - | - | - | ||
| - | - | - | ||
| - | 214,611 | 117,110 |
| - | - | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | ||||||||
| - | - | - | ||||||||
| - | 214,611 | 117,110 |
| - | 22,018 | 11,537 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| - | 4,690 | 5,626 | ||||||||
| - | 5,550 | 8,318 | ||||||||
| - | 76,071 | 60,127 | ||||||||
| - | 89 | 1,409 | ||||||||
| - | 2,250 | 5,734 | ||||||||
| - | 920 | 629 | ||||||||
| - | 5,105 | 3,708 | ||||||||
| - | 2,979 | 823 | ||||||||
| - | - | 7,200 | ||||||||
| - | 73,431 | 53,617 | ||||||||
| - | 2,248 | 255 | ||||||||
| - | 3,807 | 30 | ||||||||
| - | 2,500 | 2,500 | ||||||||
| - | 201,658 | 161,511 | ||||||||
| - | - | 1,247 | ||
|---|---|---|---|---|
| - | - |
| 1,247 | ||
|---|---|---|
| 162,758 | ||
| 12,953 | - 45,650 | |
| - | - | |
| 150,624 | 196,275 | |
| 163,577 | 150,625 |
| of the period | ||
|---|---|---|
| to nearest £ - - 163,577 OK to nearest £ - - - - - - Unrestricted funds Unrestricted funds |
Restricted funds to nearest £ - - - - OK Restricted funds to nearest £ - - - - - - |
to nearest £ Endowment funds |
| - | ||
| - | ||
| - | ||
| - | ||
| OK | ||
| to nearest £ Endowment funds |
||
| - | - | - |
| - | - | - |
| - | - | - |
| - | - | - |
| - | - | - |
| - | - | - |
| Fund to which asset belongs Fund to which asset belongs |
Cost (optional) - - - - - Cost (optional) - - - |
Current value (optional) |
|---|---|---|
| - | ||
| - | ||
| - | ||
| - | ||
| - | ||
| Current value (optional) |
||
| - | - | |
| - | - | |
| - | - |
| - | - | |
|---|---|---|
| - | - | |
| - | - | |
| - | - | |
| - | - | |
| - | - |
| Fund to which liability relates |
12,672 - - - - Amount due (optional) |
When due (optional) |
|---|---|---|
| 12,672 | ||
| - | ||
| - | ||
| - | ||
| - |
Print Name Date of approval
Independent Examiner's Report to the Trustees of Radiotherapy UK
I report to the trustees on my examination of the accounts of Radiotherapy UK for the year ended 22 June 2025.
Responsibilities and basis of report
As the charity trustees you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011. (‘the Act’).
I report in respect of my examination of the Trust’s accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.
Independent examiner’s statement
I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:
-
Accounting records were not kept in respect of the Trust as required by section 130 of the Act; or
-
The accounts do not accord with those records.
I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report to enable a proper understanding of the accounts to be reached.
Susan Redmond FCA DJH Manchester Limited St George's House 56 Peter Street Manchester M2 3NQ
9[th ] January 2026
RADIOTHERAPY UK YEAR ENDED 22 JUNE 2025 NOTES TO ACCOUNTS
Interest-free loan
The charity received an interest-free loan from Price Jones Limited, a company in which one of the trustees Professor Patricia Price is a director and shareholder. The loan currently stands at £12,672 and is repayable at £2,500 per annum beginning 1 July 2017.
Related party transactions
During the year there was a further £2,374 (2024: £4,676) paid to Professor Pat Price Limited. These were for general administrative costs. All transactions were considered to be at arm’s length.
During the year donations of £38,017 (2024:£40,000) were received from Radiotherapy4Life Limited, a company in which one of the trustees Patricia Price is a director and shareholder. Donations of £5,000 were received from Professor Pat Price Limited, a company in which Patricia Price is also a director.